Literature DB >> 24804175

Hepatic iron overload and hepatocellular carcinoma.

Michael C Kew1.   

Abstract

In recent years it has become increasingly evident that excess body iron may be complicated by the supervention of hepatocellular carcinoma (HCC). Hereditary hemochromatosis (HH) was the first condition in which hepatic iron overload was shown to predispose to the development of HCC. The inherited predisposition to excessive absorption of dietary iron in HH is almost always the result of homozygosity of the C282Y mutation of the HFE gene, which causes inappropriately low secretion of hepcidin. HCC develops in 8-10% of patients with HH and is responsible for approximately 45% of deaths in the HCC patients. Cirrhosis is almost always present when HCC is diagnosed. Dietary iron overload is a condition which occurs in rural-dwelling Black Africans in southern Africa as a result of the consumption, over time, of large volumes of alcohol home-brewed in iron containers and having, as a consequence, a high iron content. Iron loading of the liver results and may be complicated by malignant transformation of the liver (relative risk of approximately 10.0). Accompanying cirrhosis does occur but is less common than that in HH. The development of HCC as a consequence of increased dietary iron, and the fact that it may develop in the absence of cirrhosis, has been confirmed in an animal model. Drinking water with a high iron content might contribute to the high incidence of HCC in parts of Taiwan. The metabolic syndrome [obesity, insulin resistance type 2 (or diabetes mellitus type 2), non-alcoholic fatty liver or non-alcoholic steatohepatitis] has in recent years become a major public health problem in some resource-rich countries. A link between excess body iron and insulin resistance or the metabolic syndrome has become apparent. The metabolic syndrome may be complicated by the supervention of HCC, and recent evidence suggests that increased body iron may contribute to this complication.

Entities:  

Keywords:  Cirrhosis; Dietary iron overload; Excess body iron; Hepatocellular carcinoma; Hereditary hemochromatosis

Year:  2014        PMID: 24804175      PMCID: PMC3995380          DOI: 10.1159/000343856

Source DB:  PubMed          Journal:  Liver Cancer        ISSN: 1664-5553            Impact factor:   11.740


  72 in total

1.  Up-regulation of transferrin receptor 1 in chronic hepatitis C: Implication in excess hepatic iron accumulation.

Authors:  Hiroyuki Saito; Yoshinori Fujimoto; Takaaki Ohtake; Yasuaki Suzuki; Shinobu Sakurai; Yayoi Hosoki; Katsuya Ikuta; Yoshihiro Torimoto; Yutaka Kohgo
Journal:  Hepatol Res       Date:  2005-04       Impact factor: 4.288

2.  Duration of hepatic iron exposure increases the risk of significant fibrosis in hereditary hemochromatosis: a new role for magnetic resonance imaging.

Authors:  John K Olynyk; Timothy G St Pierre; Robert S Britton; Elizabeth M Brunt; Bruce R Bacon
Journal:  Am J Gastroenterol       Date:  2005-04       Impact factor: 10.864

3.  Iron overload in urban Africans in the 1990s.

Authors:  I T Gangaidzo; V M Moyo; T Saungweme; H Khumalo; R M Charakupa; Z A Gomo; M Loyevsky; R Stearman; T La Vaute; E G Enquist; T A Rouault; V R Gordeuk
Journal:  Gut       Date:  1999-08       Impact factor: 23.059

4.  Prevalence of type 2 diabetes mellitus among persons with hepatitis C virus infection in the United States.

Authors:  S H Mehta; F L Brancati; M S Sulkowski; S A Strathdee; M Szklo; D L Thomas
Journal:  Ann Intern Med       Date:  2000-10-17       Impact factor: 25.391

5.  Liver iron excess in patients with hepatocellular carcinoma developed on non-alcoholic steato-hepatitis.

Authors:  Paolo Sorrentino; Salvatore D'Angelo; Umberto Ferbo; Pietro Micheli; Alessandra Bracigliano; Raffaela Vecchione
Journal:  J Hepatol       Date:  2008-11-14       Impact factor: 25.083

6.  Iron in NASH, chronic liver diseases and HCC: how much iron is too much?

Authors:  Antonello Pietrangelo
Journal:  J Hepatol       Date:  2008-12-04       Impact factor: 25.083

7.  Biochemical and biophysical investigations of the ferrocene-iron-loaded rat. An animal model of primary haemochromatosis.

Authors:  R J Ward; A L Florence; D Baldwin; C Abiaka; F Roland; M H Ramsey; D P Dickson; T J Peters; R R Crichton
Journal:  Eur J Biochem       Date:  1991-12-05

8.  Receptor-modulated iron release from transferrin: differential effects on N- and C-terminal sites.

Authors:  P K Bali; P Aisen
Journal:  Biochemistry       Date:  1991-10-15       Impact factor: 3.162

9.  Hereditary haemochromatosis and hepatocellular carcinoma in males: a strategy for estimating the potential for primary prevention.

Authors:  J E Haddow; G E Palomaki; M McClain; W Craig
Journal:  J Med Screen       Date:  2003       Impact factor: 2.136

10.  Geographic patterns of hepatocellular carcinoma mortality with exposure to iron in groundwater in Taiwanese population: an ecological study.

Authors:  Horng-Jeng Shyu; Chia-Chi Lung; Chien-Chang Ho; Yi-Hua Iris Sun; Pei-Chieh Ko; Jing-Yang Huang; Chia-Chen Pan; Yi-Chen Chiang; Shih-Chang Chen; Yung-Po Liaw
Journal:  BMC Public Health       Date:  2013-04-16       Impact factor: 3.295

View more
  54 in total

1.  Iron overload correlates with serum liver fibrotic markers and liver dysfunction: Potential new methods to predict iron overload-related liver fibrosis in thalassemia patients.

Authors:  Man Wang; Rongrong Liu; Yuzhen Liang; Gaohui Yang; Yumei Huang; Chunlan Yu; Kaiqi Sun; Yongrong Lai; Yang Xia
Journal:  United European Gastroenterol J       Date:  2016-06-23       Impact factor: 4.623

Review 2.  Iron-based phosphate binders: a paradigm shift in the treatment of hyperphosphatemic anemic CKD patients?

Authors:  Francesco Locatelli; Lucia Del Vecchio
Journal:  J Nephrol       Date:  2017-07-17       Impact factor: 3.902

3.  Combined histological and hematological assessment of iron-induced organ damage in a gerbil model of iron overload.

Authors:  Man Wang; Rong-Rong Liu; Cong-Jun Wang; Wei Kang; Gao-Hui Yang; Wu-Ning Zhong; Yong-Rong Lai
Journal:  Am J Transl Res       Date:  2015-02-15       Impact factor: 4.060

4.  MRI-based R2* mapping in patients with suspected or known iron overload.

Authors:  Emre Aslan; Jack W Luo; An Lesage; Philippe Paquin; Milena Cerny; Anne Shu-Lei Chin; Damien Olivié; Guillaume Gilbert; Denis Soulières; An Tang
Journal:  Abdom Radiol (NY)       Date:  2021-01-02

Review 5.  Nutrition and Hepatocellular Cancer.

Authors:  Kerstin Schütte; Christian Schulz; Peter Malfertheiner
Journal:  Gastrointest Tumors       Date:  2015-11-18

6.  Quantification of liver fat with respiratory-gated quantitative chemical shift encoded MRI.

Authors:  Utaroh Motosugi; Diego Hernando; Peter Bannas; James H Holmes; Kang Wang; Ann Shimakawa; Yuji Iwadate; Valentina Taviani; Jennifer L Rehm; Scott B Reeder
Journal:  J Magn Reson Imaging       Date:  2015-04-01       Impact factor: 4.813

7.  Convergence of hepcidin deficiency, systemic iron overloading, heme accumulation, and REV-ERBα/β activation in aryl hydrocarbon receptor-elicited hepatotoxicity.

Authors:  Kelly A Fader; Rance Nault; Mathew P Kirby; Gena Markous; Jason Matthews; Timothy R Zacharewski
Journal:  Toxicol Appl Pharmacol       Date:  2017-02-16       Impact factor: 4.219

8.  Iron depletion enhances the effect of sorafenib in hepatocarcinoma.

Authors:  Shinichi Urano; Toshiaki Ohara; Kazuhiro Noma; Ryoichi Katsube; Takayuki Ninomiya; Yasuko Tomono; Hiroshi Tazawa; Shunsuke Kagawa; Yasuhiro Shirakawa; Fumiaki Kimura; Kazuhiro Nouso; Akihiro Matsukawa; Kazuhide Yamamoto; Toshiyoshi Fujiwara
Journal:  Cancer Biol Ther       Date:  2016-04-18       Impact factor: 4.742

9.  Hemochromatosis: a model of metal-related human toxicosis.

Authors:  Pierre Brissot; Thibault Cavey; Martine Ropert; François Gaboriau; Olivier Loréal
Journal:  Environ Sci Pollut Res Int       Date:  2016-09-15       Impact factor: 4.223

10.  Decreasing iron-related indexes without anaemia in a patient with genetic haemochromatosis.

Authors:  Clara Benedetta Conti; Alessandra Baccarin; Dario Conte; Mirella Fraquelli
Journal:  Intern Emerg Med       Date:  2015-07-26       Impact factor: 3.397

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.